News

Traditional therapy includes anti-VEGF injections into the eye. This is effective in many patients, but some remain unresponsive. Recent studies have suggested this new target.

Seizures were well controlled for up to 6 years in some patients with epilepsy receiving perampanel for partial onset seizures.

The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.

A descriptive review of 150-plus papers on drug-induced interstitial lung disease shows there is an absence of high-quality data on the disease.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.

Patients may have been told they would ‘grow out of’ PKU, and consequently go off-diet, with consequences such as cognitive deficit.

A new meta-analysis finds people who were recently incarcerated face significantly higher risks of contracting hepatitis C and HIV infection.

A study of deep brain stimulation in patients with tardive dyskinesia and dystonia reports promising results.

Medical options can include oral contraceptives, pain medications, hormonal therapies, and gonadotropin-releasing hormone (GnRH) agonists.

The FDA has extended the approved use of Bryhali (halobetasol propionate) Lotion .01% for up to 8 weeks in adults with plaque psoriasis.

A retrospective review finds HIV post-exposure prophylaxis is often prescribed outside of guidelines’ recommendations in response to patients' emotional stress.

Researchers have long associated HIV exposure with a heightened risk of congenital cytomegalovirus in infants. However, new research finds the risk is highest if HIV is contracted during the pregnancy.

Until recently, studies of systemic corticosteroids in pneumonia have yielded contradicting results, while studies in acute exacerbation of COPD have shown significant benefits.

A new, fundamental biological process in CLN8 disease, a form of Batten disease, has been discovered by a team of investigators from Baylor College of Medicine.

For patients with inflammatory bowel disease (IBD) and C difficile, immunosuppressive therapy escalation for IBD, after treatment for the infection, was not associated with adverse outcomes.

Treatment regimens comprised of DCV+SOF±RBV and VEL/SOF+RBV offer similar cure rates among HCV patients with genotypes 2 and 3.

A new study found that almost all humans have a less active form of interferon lambda 4, a fact that leaves them vulnerable to HCV.

The 4th generation VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator has been approved by the FDA for use on the VITROS 5600 Integrated System.

The FDA has accepted Sanofi’s supplemental biologics license application (sBLA) for priority review of dupilumab (Dupixent) in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Eslicarbazepine in combination with lamotrigine is better tolerated than when combined with carbamazepine for focal seizures.

Adolescents living with HIV suffer fewer disease-related symptoms when they and a family member plan for end-of-life care.

Treatment with crizanlizumab reduced pain in patients with sickle cell disease who were experiencing vaso-occlusive crisis.

Levetiracetam found superior to carbamazepine and valproate sodium in reducing Rolandic discharges on EEG of children with Rolandic epilepsy.

When providers fail to recognize and combat stigma in their ranks, undiagnosed persons with HIV may go unidentified and fail to get quality care and treatment.

A new review of literature about 2 anti-VEGF therapies for diabetic macular edema suggest the drugs hold promise, but not without some caveats.

Cannabidiol (Epidiolex), the first FDA-approved plant-derived cannabinoid medicine in the United States, is now available by prescription for patients with seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.